The demographic characteristics and health-related quality of life in a large cohort of reflux esophagitis patients in Japan with reference to the effect of lansoprazole: the REQUEST study.

Abstract

BACKGROUND:

Patients with reflux esophagitis (RE) in Western countries have impaired health-related quality of life (HRQOL). However, few data are available concerning HRQOL in Asian patients with RE.

AIM:

To determine the demographic characteristics, HRQOL, and the impact of lansoprazole treatment in a large cohort of RE patients in Japan.

METHODS:

Patients with RE were enrolled. Lansoprazole was administered for 8 weeks and HRQOL assessed using the SF-8 and a newly developed questionnaire for RE-specific HRQOL (RESQ) at baseline and after 4 and 8 weeks of treatment.

RESULTS:

Among enrolled patients, 2320 patients with the Los Angeles classification grade A to D esophagitis at enrollment to the study were analyzed. A higher proportion of older women was observed (in the group of patients aged >or=60 years, 61.3% were women). Prevalence of obesity was 4.7%. At baseline, HRQOL scores of RE patients were well below the mean for the Japanese general population in all domains of the SF-8. After 8 weeks of treatment with lansoprazole, these scores significantly improved to the levels of the general population (P < 0.01). Scores of RESQ also significantly improved (P < 0.01).

CONCLUSIONS:

Demographically, RE patients in Japan differ from those in Western countries with an increased proportion in older women and lower prevalence of obesity. RE has a marked negative impact on HRQOL, which is significantly improved by treatment with lansoprazole.

• Authors: Michio Hongo, Yoshikazu Kinoshita, Hiroto Miwa, Kiyoshi Ashida
• Journal: Journal of gastroenterology (J Gastroenterol) Vol. 43 Issue 12 Pg. 920-7 ( 2008) ISSN: 0944-1174 [Print] Japan
• PMID: 19107335 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• 2-Pyridinylmethylsulfinylbenzimidazoles
• Anti-Ulcer Agents
• Lansoprazole

Topics

• 2-Pyridinylmethylsulfinylbenzimidazoles (therapeutic use)
• Adult
• Age Factors
• Aged
• Anti-Ulcer Agents (therapeutic use)
• Esophagitis, Peptic (complications, drug therapy, epidemiology)
• Female
• Health Surveys
• Humans
• Japan (epidemiology)
• Lansoprazole
• Male
• Middle Aged
• Obesity (complications)
• Product Surveillance, Postmarketing (statistics & numerical data)
• Quality of Life
• Severity of Illness Index
• Sex Factors